Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks

Human Pathology

Volumn 46, Issue 6, 2015, Pages 850-857

  Ge, Xiaowen ^a   Wang, Haixing ^a   Zeng, Haiying ^a   Jin, Xuejuan ^a   Sujie, Akesu ^a   Xu, Chen ^a   Liu, Yalan ^a   Huang, Jie ^a   Ji, Yuan ^a   Tan, Yunshan ^a   Liu, Tianshu ^a   Hou, Yingyong ^a   Qin, Jing ^a   Sun, Yihong ^a   Qin, Xinyu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Dual paraffin blocks; Gastric cancer; Her2 neu; Immunohistochemistry; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PARAFFIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; DUAL TUMOR TISSUE PARAFFIN BLOCK; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PROCEDURES; MAJOR CLINICAL STUDY; MALE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STOMACH CANCER; CANCER STAGING; GENE AMPLIFICATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; STOMACH TUMOR; TISSUE PRESERVATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PARAFFIN; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TISSUE PRESERVATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84937965317     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.02.011     Document Type: Article

References (34)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. K. Sugano Gastric cancer: pathogenesis, screening, and treatment Gastrointest Endosc Clin N Am 18 2008 513 522
3. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
4. W. Tai, R. Mahato, and K. Cheng The role of HER2 in cancer therapy and targeted drug delivery J Control Release 146 2010 264 275
5. C. Gravalos, and A. Jimeno HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Ann Oncol 19 2008 1523 1529
6. A.H. Marx, L. Tharun, J. Muth, and et al. HER-2 amplification is highly homogenous in gastric cancer Hum Pathol 40 2009 769 777
7. J.T. Jorgensen Targeted HER2 treatment in advanced gastric cancer Oncology 78 2010 26 33
8. K. Sakai, S. Mori, T. Kawamoto, and et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas J Natl Cancer Inst 77 1986 1047 1052
9. P. Lauren The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification Acta Pathol Microbiol Scand 64 1965 31 49
10. H. Allgayer, R. Babic, K.U. Gruetzner, A. Tarabichi, F.W. Schildberg, and M.M. Heiss c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems J Clin Oncol 18 2000 2201 2209
11. T. Takehana, K. Kunitomo, K. Kono, and et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay Int J Cancer 98 2002 833 837
12. A.R. Tan, and S.M. Swain Ongoing adjuvant trials with trastuzumab in breast cancer Semin Oncol 30 2003 54 64
13. D.H. Roukos Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance Ann Surg Oncol 17 2010 14 17
14. N.J. Petrelli, E.P. Winer, J. Brahmer, and et al. Clinical cancer advances 2009: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology J Clin Oncol 27 2009 6052 6069
15. Y.J. Bang, E. Van Cutsem, A. Feyereislova, and et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
16. J.S. Ross, E.A. Slodkowska, W.F. Symmans, L. Pusztai, P.M. Ravdin, and G.N. Hortobagyi The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 2009 320 368
17. G.D. Francis, M.A. Jones, G.F. Beadle, and S.R. Stein Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome Diagn Mol Pathol 18 2009 88 95
18. M. Hofmann, O. Stoss, D. Shi, and et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 2008 797 805
19. J. Ruschoff, M. Dietel, G. Baretton, and et al. HER2 diagnostics in gastric cancer - guideline validation and development of standardized immunohistochemical testing Virchows Arch 457 2010 299 307
20. C. Albarracin, M.E. Edgerton, M.Z. Gilcrease, and et al. Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med 134 2010 162 163 [author reply 163]
21. H. Seol, H.J. Lee, Y. Choi, and et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance Mod Pathol 25 2012 938 948
22. J.A. Ajani, J.S. Barthel, T. Bekaii-Saab, and et al. Gastric cancer J Natl Compr Canc Netw 8 2010 378 409
23. F.T. Bosman, F. Carneiro, R.H. Hruban, and N.D. Theise WHO classification of tumours of the digestive system 2010 International Agency for Research on Cancer (IARC) Lyon, France
24. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind TNM classification of malignant tumours 7th ed. 2009 Wiley-Blackwell Oxford
25. V.S. Warneke, H.M. Behrens, C. Boger, and et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors Ann Oncol 24 2013 725 733
26. C. Bozzetti, F.V. Negri, C.A. Lagrasta, and et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma Br J Cancer 104 2011 1372 1376
27. S.C. Abraham, S.J. Park, J.H. Lee, L. Mugartegui, and T.T. Wu Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes Mod Pathol 16 2003 786 795
28. M.A. Kim, H.J. Lee, H.K. Yang, Y.J. Bang, and W.H. Kim Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma Histopathology 59 2011 822 831
29. L.J. Tafe, Y.Y. Janjigian, M. Zaidinski, and et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization Arch Pathol Lab Med 135 2011 1460 1465
30. B. Yan, E.X. Yau, S.S. Bte Omar, and et al. A study of HER2 gene amplification and protein expression in gastric cancer J Clin Pathol 63 2010 839 842
31. W.R. Sukov, A.C. Duek, K.S. Tenner, and et al. Benefit of adjuvant trastuzumab in breast cancer patients with focal HER-2 amplified colonies: data from N9831 Intergroup Adjuvant Trial [abstract] J Clin Oncol 15s 2009 520 [Suppl.]
32. V. Arena, I. Pennacchia, F.M. Vecchio, and A. Carbone HER-2 intratumoral heterogeneity Mod Pathol 26 2013 607 609
33. Consensus workshop e Raccomandazioni sull'impiego delle diverse metodiche per la determinazione dello stato di HER2 nel carcinoma mammario e nel carcinoma gastrico Catania 2010
34. M. Tanner, M. Hollmen, T.T. Junttila, and et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 2005 273 278